Ultrasound therapy developer ImaRx Therapeutics of Tucson, AZ, has begun clinical trials to investigate the use of its SonoLysis technology for the treatment of blood clots in kidney dialysis patients whose access grafts have become blocked.
The SonoLysis technique combines the use of ultrasound and the firm’s microbubble clot agent to potentially dissolve vascular thromboses in noninvasive procedures. The microbubble agent is a gas-filled lipid sphere that is smaller than a red blood cell, according to the company.
The phase I/II multicenter clinical trial will enroll 24 patients whose kidney dialysis access grafts have become blocked due to blood clots. In these studies, microbubbles will be administered to the clot-blocked graft and three different levels of ultrasound will be applied to determine the safety and efficacy of the SonoLysis technology.
In addition to clinical trials of SonoLysis for dialysis graft clots, the company said it is planning on filing an investigational new drug (IND) application with the Food and Drug Administration for deep-vein thrombosis treatment.
By AuntMinnie.com staff writersSeptember 18, 2003
Related Reading
Ultrasound bubbles over into therapy, February 12, 2001
Copyright © 2003 AuntMinnie.com
